Making a
difference.
It's in our DNA.

Ling Huang, PhD

Research Assistant Professor, Henry Ford Health System
Pharmacology and Toxicology
313-916-1554
Henry Ford Hospital - Detroit

Associations

  • Henry Ford Health System

Education

  • PhD, Biological Sciences, Purdue University West Lafayette (2003-08-30—2009-05-01)
  • B.S., Biochemistry, East China University of Science and Technology (1999-09-04—2003-06-27)

Funding

  • investigate therapeutic potentials of EZH2 targeting in pancreatic cancer using patient derived organoids, Hirshberg Foundation for Pancreatic Cancer Research ()
  • Circulating tumor cells for predicting pancreatic cancer patient responses to chemotherapies, National Foundation for Cancer Research ()

Works

  • Abnormal exocrine--endocrine cell cross-talk promotes $β$-cell dysfunction and loss in MODY8. Nature Metabolism (2022)
  • Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. Clinical Cancer Research (2022)
  • Personalized tumor vaccine for pancreatic cancer. Cancer Immunology, Immunotherapy (2022)
  • Commitment and oncogene-induced plasticity of human stem cell-derived pancreatic acinar and ductal organoids. Cell Stem Cell (2021)
  • Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids. Journal for immunotherapy of cancer (2021)
  • Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Science Advances (2021)
  • Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor CellsSingle-cell RNA-seq to Uncover Metastatic Targets in PDAC. Molecular Cancer Therapeutics (2020)
  • Discovery of a selective inhibitor of doublecortin like kinase 1. Nature chemical biology (2020)
  • PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI insight (2020)
  • Synthesis and Structure--Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5, 11-Dihydro-6 H-benzo [e] pyrimido [5, 4-b][1, 4] diazepin-6-one Scaffold. Journal of medicinal chemistry (2020)
  • Personalized RNA medicine for pancreatic cancer. Clinical Cancer Research (2018)
  • Reversing the direction of galvanotaxis with controlled increases in boundary layer viscosity. Physical biology (2018)
  • Prostate cancer--associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature medicine (2017)
  • Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell--and patient-derived tumor organoids. Nature medicine (2015)
  • Epidermal keratinocyte polarity and motility require Ca2+ influx through TRPV1. Journal of cell science (2013)
  • Rotational motion during three-dimensional morphogenesis of mammary epithelial acini relates to laminin matrix assembly. Proceedings of the National Academy of Sciences (2013)
  • Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators. Current opinion in genetics & development (2010)
  • The involvement of Ca2+ and integrins in directional responses of zebrafish keratocytes to electric fields. Journal of cellular physiology (2009)
  • Chick embryonic Schwann cells migrate anodally in small electrical fields. Experimental neurology (2008)
  • A novel strategy to identify the regulatory DNA-organized cooperations among transcription factors. FEBS letters (2006)

Employment

  • Assistant Professor, Michigan State University ()
  • Assistant Scientist, Henry Ford Health System (2022-01-17)
  • Instructor, Beth Israel Deaconess Medical Center (2015-11-19—2021-01-08)
  • Research Fellow, Princess Margaret Hospital Cancer Centre (2009-01-10—2015-11-18)
  • Graduate Student, Purdue University (2003-08-17—2009-01-20)